RNA-Dependent Protein Kinase Is Essential for 2-Methoxyestradiol-Induced Autophagy in Osteosarcoma Cells

Caihong Yang¹², Kristen L. Shogren¹, Ribu Goyal¹, Dalibel Bravo¹, Michael J. Yaszemski¹, Avudaiappan Maran¹*¹

¹Department of Orthopedics, Mayo Clinic, Rochester, Minnesota, United States of America, ²Department of Orthopedic, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Abstract
Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Surgical resection and adjunctive chemotherapy are the only widely available options of treatment for this disease. Anti-tumor compound 2-Methoxyestradiol (2-ME) triggers cell death through the induction of apoptosis in osteosarcoma cells, but not in normal osteoblasts. In this report, we have investigated whether autophagy plays a role in 2-ME actions on osteosarcoma cells. Transmission electron microscopy imaging shows that 2-ME treatment leads to the accumulation of autophagosomes in human osteosarcoma cells. 2-ME induces the conversion of the microtubule-associated protein LC3-I to LC3-II, a biochemical marker of autophagy that is correlated with the formation of autophagosomes. Conversion to LC3-II is accompanied by protein degradation in 2-ME-treated cells. 2-ME does not induce autophagosome formation in normal primary human osteoblasts. In addition, 2-ME-dependent autophagosome formation in osteosarcoma cells requires ATG7 expression. Furthermore, 2-ME does not induce accumulation of autophagosomes in osteosarcoma cells that express dominant negative mutant RNA-dependent protein kinase (PKR) and are resistant to anti-proliferative and anti-tumor effects of 2-ME. Taken together, our study shows that 2-ME treatment induces PKR-dependent autophagy in osteosarcoma cells, and that autophagy could play an important role in 2-ME-mediated anti-tumor actions and in the control of osteosarcoma.

Citation: Yang C, Shogren KL, Goyal R, Bravo D, Yaszemski MJ, et al. (2013) RNA-Dependent Protein Kinase Is Essential for 2-Methoxyestradiol-Induced Autophagy in Osteosarcoma Cells. PLoS ONE 8(3): e59406. doi:10.1371/journal.pone.0059406

Introduction
Autophagy is a regulatory event that involves lysosomal degradation of cytoplasmic organelles or cytosolic components [1]. Autophagy occurs due to cellular stress, starvation, hypoxia, cancer or other pathological conditions, and is a multi-step regulatory event involving several signal pathways. Autophagy can be pro- or anti-tumorigenic in nature [2–5]. In some instances, autophagy could block cancer cells against drug-induced cytotoxic effects and apoptosis. In other cases, tumor cells can be subjected to autophagic cell death after anti-cancer therapy. Several reports indicate that autophagy may contribute to the survival of established tumors by facilitating chemoresistance during cancer therapy [6–10]. On the contrary, autophagy mediates the cytotoxic or cytostatic effect of several anticancer and chemotherapeutic agents suggesting that autophagy could serve as a tumor suppressor event [11–14]. Osteosarcoma is a common pediatric tumor which mostly originates in the growing ends of bones and primarily affects children and adolescents. It is the second most common tumor among children who are 15 years of age or younger. Although the overall incidence is low, about 30% of patients diagnosed with osteosarcoma will develop metastatic diseases. Although surgery and chemotherapy have improved the survival in the last decades, a highly successful treatment is not yet available for this disease. 2-Methoxyestradiol (2-ME) is a naturally occurring metabolite of 17β-estradiol and is an inhibitor of tumor cell proliferation in various types of cancer [15–21]. 2-ME has been shown to block cell proliferation and induce cell cycle arrest and apoptosis in osteosarcoma cells [22–24]. 2-ME-mediated anti-tumor actions require RNA-dependent protein kinase (PKR) in osteosarcoma cells. In this report, we have investigated whether 2-ME actions involve autophagy in osteosarcoma cells.

Materials and Methods

Cell Culture
Human osteoblast (HOB) cells and osteosarcoma cells MG63 and KHOS [23–26] were cultured in DMEM/F12 media at 37°C and treated with vehicle control and 2-ME, as indicated.

Transmission Electron Microscopy (TEM)
Cells were grown on aclar in tissue culture plates, treated with vehicle or 10 μM 2-ME for 48 hours and then fixed with Trump's...
fixative and processed for TEM at Mayo Clinic's electron microscopy core facility.

LC3-GFP Assay

MG63 cells were transfected in triplicate with EGFP-LC3B using FuGene-HD transfection reagent (Roche Applied Science, Indianapolis, IN) and treated with vehicle or 10 μM 2ME. Punctate fluorescent staining was visualized by confocal microscopy. The quantitation of punctae was carried out by counting 6 fields for each treatment.

Figure 1. 2-ME Induces autophagosomes in osteosarcoma cells. Osteosarcoma cells were treated with vehicle (Veh) and 2-ME (10 μM) for 48 hrs and analyzed using TEM. A) TEM images of MG63 cells: Veh 30000X (i); 2-ME 30000X (ii); 2-ME 60000X (iii). B) TEM images of KHOS cells; Veh 25000X (i); 2-ME 25000X (ii); 2-ME40000X (iii).

doi:10.1371/journal.pone.0059406.g001

Figure 2. 2-ME does not induce autophagosomes in HOB cells. HOB cells were treated with Veh and 2-ME (10 μM) for 48 hrs and analyzed using TEM. Veh 30000X (i); 2-ME 30000X (ii); 2-ME 40000X (iii).

doi:10.1371/journal.pone.0059406.g002
Cytoplasmic extracts from vehicle- and 2-ME-treated cells were analyzed by western blot hybridization using anti-LC3-I/II and anti-actin antibodies. The bands were analyzed by quantitative densitometry. After western blot analysis, the signals from the corresponding bands were quantitated and the ratio of LC3-II over LC3-I was determined after normalization to actin. A) Western analysis; B) Quantitation of the blot.

**Western Analysis**

Cytoplasmic extracts from vehicle- and 2-ME-treated cells were analyzed by western blot hybridization using anti-LC3-I/II, anti-ATG7 (Cell Signaling Technology, Beverly, MA) and anti-actin (Sigma, St. Louis, MO) antibodies. Quantitation was performed by densitometry and analyzed using Quantity One software (Bio-Rad, Hercules, CA).

**Coimmunoprecipitation Assay**

Coimmunoprecipitation was carried out as described [27]. Briefly, cell extracts containing equal amounts of protein were immunoprecipitated using anti-LC3B antibodies, or non-immune IgG. The immunoprecipitated proteins were incubated with protein A Sepharose for 1 hr at 4°C and then washed and analyzed by western blot using anti-p62 and anti-LC3B antibodies (Cell Signaling Technology).

**SiRNA Transfection**

siRNA-mediated inhibition of gene expression: Osteosarcoma cells (5 x 10⁴) in 24-well plates were transfected with a pool of ATG7 siRNAs [i] CCAACACACUGAGUCUUU; ii) GAUCUAAAUCUAAACUGA; iii) GCCCACAGAUGUGAAGCA; iv) GCCAGAGGAUUGCAACAU] and control non-targeting siRNAs [5’TGGUUUCAGUGCGACUAAS’T] as per the manufacturer’s protocol (Dharmacon, Lafayette, CO). Twenty-four hrs after transfection, cells were treated with vehicle control and 2-ME (10 μM). At the end of 24 hrs of treatment, cells will be processed for TEM and western blot hybridization as described above.

**Protein Degradation Assay**

Osteosarcoma cells were plated and the following day, 2 μCi of 1H-L-valine was added and incubated for 24 hrs. Then the cells were rinsed and treated with vehicle and 10 μM 2-ME in fresh media. The media were collected at different time intervals and 1 X cell lysis buffer was used to lyse the cells. The radioactivity was determined by precipitating with 10% trichloroacetic acid and counting in a scintillation counter. The protein degradation was determined by the ratio of label in the media to the cells.

**Statistical Analysis**

All values are expressed as mean±standard error. The data is representative of three independent experiments. Significant differences between groups were determined by Fisher’s protected least significant difference post hoc test for multiple-group comparisons, following detection of significance by one-way analysis of variance (ANOVA). P<0.05 was considered statistically significant.

**Results**

2-ME Induces Autophagosome Formation in Osteosarcoma Cells

To determine the effect of 2-ME on autophagy, we have investigated whether 2-ME induces autophagic vacuoles in osteosarcoma cells. The results show that multimembrane vacuoles
are formed after 48 hrs in 2-ME-treated MG63 and KHOS osteosarcoma cells, as shown in transmission electron microscopy images (Fig. 1A & 1B). The control (vehicle-treated cells) does not show any multimembrane vacuole formation (Fig. 1A & 1B). Furthermore, our results show that 2-ME does not induce autophagic vacuoles in primary human osteoblast cells (HOB) suggesting that the effect is specific to tumor cells (Fig. 2).

2-ME Induces the Conversion of LC3-I to LC3-II

The autophagosome-associated protein, microtubule-associated protein 1 light chain 3 (LC3), has been implicated as a marker of

![Figure 5](https://example.com/figure5.png)

**Figure 5. Puncta formation and quantitation in 2-ME-treated cells.** LC3-GFP-transfected MG63 osteosarcoma cells were treated with vehicle and 10 μM 2-ME for 16 hrs. GFP-LC3 dots per GFP-LC3-transfected cells were scored after analysis by fluorescence microscopy (A) Upper panel: fluorescence; Lower panel: fluorescence+ VISIBLE. B) Quantitation of Puncta. *P<0.05 compared to Veh.

doi:10.1371/journal.pone.0059406.g005

![Figure 6](https://example.com/figure6.png)

**Figure 6. 2-ME increases protein degradation in MG63 cells.** 14C-valine-labeled MG63 cells were treated with vehicle and 10 μM 2-ME for various time points and the protein degradation was analyzed as described in Methods. *P<0.05 compared to Veh.

doi:10.1371/journal.pone.0059406.g006
autophagy. During autophagy, LC3 type II, the membrane bound form, increases due to conversion from type I, the cytosolic form. 2-ME treatment induces the accumulation of autophagy marker LC3-II in MG63 and KHOS osteosarcoma cells, compared to the vehicle control (Fig. 3 and 4). The ratio of LC3-II to LC3-I increases in MG63 cells in the presence of 2-ME to 15-fold and 11-fold at 16 and 24 hrs, respectively (Fig. 3). Similarly in KHOS cells, the LC3-II to LC3-I ratio increases at 24 hrs to 5-fold (Fig. 4).

In addition, we have examined autophagy by following the effect of 2-ME in osteosarcoma cells that have been transfected with GFP-LC3 plasmid constructs. Our results show that 2-ME treatment increased the number of punctae formed, compared to vehicle control at 16 hrs (Fig. 5A). In contrast, vehicle-treated cells showed a diffuse distribution of green fluorescence (Fig. 5A). 2-ME induces the number of punctae by 3-fold (Fig. 5B).

2-ME Induces Protein Degradation in Osteosarcoma Cells
We have investigated whether induction of autophagosome is accompanied by protein degradation in 2-ME-treated cells. To measure the overall rates of protein degradation, vehicle- and 2-ME-treated MG63 cells were radio labeled by exposure to [14C] valine, and the rate of protein degradation was determined by measuring the [14C] valine release from the pre-labeled proteins into the medium at various time intervals. Compared to the control, the 2-ME treatment increased the protein degradation rate by 4.5-, 4- and 7-fold at 12, 16 and 24 hrs, respectively (Fig. 6).

The effect of 2-ME on protein degradation was further evaluated in the presence of the proteasome inhibitor MG132. As shown in Fig. 7, 2-ME, MG132 and 2-ME plus MG132 combination induced the protein degradation by 5-, 15- and 54-fold, respectively.

2-ME Treatment Regulates SQST/P62 Levels and its Association with LC3
We examined the effect of 2-ME treatment in osteosarcoma cells. Our results show that 2-ME treatment decreases P62 levels at 16 and 24 hrs (Fig. 8A) by 2- and 5-fold, respectively. In order to determine whether p62 interacts with LC3, we carried out co-immunoprecipitation studies. The results show that there is an increased interaction of p62 and LC3-II in 2-ME-treated osteosarcoma cells, compared to the control at 16 and 24 hrs (Fig. 8B).

2-ME Induces PKR-Dependent Autophagy
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e59406

SiRNA-mediated Inhibition of ATG7 Blocks Autophagosome Formation in 2-ME-treated Cells
ATG7 has been shown to be essential for lysosomal breakdown of organelles, protein and the induction mammalian autophagy. We have examined the effect of 2-ME on autophagosome formation in osteosarcoma cells that have been depleted with ATG7 expression after transfection with siRNAs directed against ATG7 gene. 2-ME treatment does not induce autophagosome formation in osteosarcoma cells transfected with ATG7 siRNAs but induces autophagosome in control cells that have been transfected with non-specific siRNAs (Fig. 9). The data presented
in Fig. 10 confirm that siRNA transfection leads to the down regulation of ATG7 protein levels without affecting the control actin levels (Fig. 10).

Inhibitors of Autophagy Block 2-ME Effects

The effects of autophagy inhibitors, bafilomycin A1 and 3-methyladenine (3MA) on 2-ME-mediated conversion of LC3-I to LC3-II and cell death were studied. Both bafilomycin A1 and 3MA blocked 2-ME-mediated conversion of LC3-I to LC3-II (Fig. 11A and 11B).

2-ME does not Induce Autophagosome Formation when PKR is Inhibited

2-ME treatment induces PKR expression and PKR activity in osteosarcoma cells [24]. To determine whether PKR is required for 2-ME-mediated autophagic flux, we have investigated the effect of 2-ME on autophagosome formation and LC3-I to LC3-II conversion, in osteosarcoma cells that have been stably-transfected with trans- dominant mutant PKR cDNAs and are defective for PKR activity and resistant to 2-ME-mediated anti-proliferative effects. 2-ME does not induce autophagosome formation in MG63

Figure 9. SiRNA-mediated inhibition of ATG7 expression blocks 2-ME-mediated autophagosome formation. MG63 osteosarcoma cells were treated with vehicle (Veh), 10 µM 2-ME, 2-ME plus 100 nM ATG7siRNA (ATG7Si) and 2-ME plus 100 nM Non specific siRNA (NSsi) for 48 hrs and analyzed using TEM.

doi:10.1371/journal.pone.0059406.g009

Figure 10. ATG7 siRNA transfection leads to down regulation of ATG7 protein. MG63 osteosarcoma cells were treated with vehicle (Veh), 10 µM 2-ME, 2-ME plus 100 nM ATG7siRNA (ATG7Si) and 2-ME plus 100 nM Non specific siRNA (NSsi) for 48 hrs and analyzed by western blot hybridization using anti-ATG7 and anti-actin antibodies.

doi:10.1371/journal.pone.0059406.g010
cells expressing mutant PKR protein (Fig. 12A). Our results show that the 2-ME-mediated conversion of LC3-I to LC3-II is inhibited in MG63 cells expressing mutant PKR and the LC3-II conversion is decreased to 4-fold compared to 8-fold observed in wild type PKR expressing MG63 cells (Fig. 12B &C).

**Discussion**

In this report, we show that 2-ME induces autophagosome formation, autophagy markers and protein degradation, in osteosarcoma cells. 2-ME induces autophagy specifically in osteosarcoma cells, as it does not induce autophagosome formation or markers of autophagy in normal osteoblasts. Our findings also show that 2-ME-mediated autophagy requires RNA-dependent protein kinase (PKR). The molecular mechanism of autophagy in tumor continues to be an important focus in many cancer models. Autophagy is regulated in various cancers, and depending on the context, it has been shown to be either pro-cancer or anti-cancer. Autophagy is induced during therapy by chemotherapeutic drugs and has been shown to mediate the cytotoxic effects of drugs [11–14]. Current results reveal that 2-ME-mediated anti-tumor actions in osteosarcoma cells need further investigations in order to fully understand the role of autophagy in osteosarcoma patients.

It has been demonstrated that during autophagy, the LC3 protein is recruited. Also, one of the early key events in autophagy is the conversion of cytoplasmic soluble LC3-I to a lipid-conjugated LC3-II form that associates with the autophagosome membranes [28–30]. The autophagic activity is measured biochemically based on the amount of LC3-II accumulation and the formation of cellular autophagosome punctae containing LC3-II [31]. The results presented here show that the conversion of LC3-I to LC3-II is induced by 2-ME treatment in osteosarcoma cells. In addition, it has been demonstrated that in GFP-LC3-transfected osteosarcoma cells, 2-ME increases the punctate form of LC3. The data also demonstrate that osteosarcoma cells transfected with siRNAs for ATG7, do not respond to 2-ME-mediated autophagosome induction, suggesting that 2-ME-mediated effects require ATG7 protein expression. Also, 2-ME does not induce autophagosome formation in normal HOB cells, implying that only cells that respond to anti-growth activities of 2-ME respond to 2-ME-stimulated formation of autophagosomes.

Our results show that increased autophagosome formation is accompanied by increased protein degradation in the presence of 2-ME treatment. We have demonstrated that proteasome inhibitor MG132 enhances 2-ME effects on protein degradation. This observation is in agreement with the published reports which indicate that inhibition of proteasome induces autophagy [32,33]. While further investigation is necessary, the combined effects of 2-ME and MG132 confirm the link between Ubiquitin-proteosome system and autophagy machinery [32,33].

The P62 protein, also known as Sequestosome 1(SQST1) has been shown to play a role in the regulation of tumor and autophagy and to aggregate to LC3 on the surface of autophagosomes [34,35]. Similarly, p62 was also localized to the autophagic compartment and constantly degraded by the autophagy-lysosome system. P62 binds to LC3 and can localize to autophagic compartments, thereby transporting ubiquitinated proteins for degradation. This event is widely used as a common hallmark of autophagy [34,35]. Our results demonstrate that there is a decrease in p62 expression but an enhanced association of p62 to LC3-II in the presence of 2-ME-treatment in osteosarcoma cells. These 2-ME-induced changes and autophagic flux are accompanied by protein degradation in osteosarcoma cells.

Our data show that the autophagy inhibitors bafilomycin A1 and 3MA, block the 2-ME-mediated conversion of LC3I to LC3II in osteosarcoma cells. While 3MA does not affect osteosarcoma cell growth, bafilomycin had a moderate induction on cell death and enhanced 2-ME-induced cell death (C. Yang, R. Goyal, K. Shogren and A. Maran, unpublished observation). Further work is necessary to evaluate the effect of bafilomycin on osteosarcoma cell death alone and in combination with 2-ME.

The morphological and molecular changes representing autophagosome and autophagic flux are blocked in the presence of PKR inhibition in 2-ME-treated cells. Our studies indicate that RNA-dependent protein kinase (PKR) is essential for the induction of autophagosome formation and the conversion of LC3-I to LC3-II. PKR plays an important role in anti-viral, anti-cancer and anti-proliferative effects. PKR activation in cells leads to phosphorylation of alpha subunit of eukaryotic initiation factor 2 (eIF2a) and subsequent shutdown of viral and cellular protein synthesis [16,36,37]. Also, PKR has been shown to induce apoptosis in cancer cells [38,39]. We have previously demonstrated that PKR plays a role in 2-ME-mediated cell cycle arrest and apoptosis in osteosarcoma cells [24,25]. Osteosarcoma cells expressing trans-dominant mutant PKR is resistant to anti-cellular and anti-tumor effects of 2-ME [24]. In this report, we show that 2-ME-mediated autophagosome formation and the conversion of LC3-I to LC3-II are inhibited in cells that express dominant negative mutant PKR protein. PKR has been implicated in the induction of autophagy during virus infection [40]. However, it has not been reported to play a role in drug-induced anti-cancer activities. DRAM (damage-regulated autophagy modulator), is a p53-induced modulator of autophagy and has been implicated in 2-ME-dependent autophagy in Ewing sarcoma cells [41]. 2-ME-mediated induction of autophagy contributes to the cytotoxic cell death in Ewing sarcoma cells [41]. Recently, a few investigations have demonstrated that 2-ME induces both apoptosis and autophagy in different models [41–44]. However, the involvement
of autophagy in 2-ME-mediated anti-proliferative actions have not been fully understood. The current results demonstrate that both autophagy and apoptosis require PKR protein in 2-ME-treated osteosarcoma cells. Our results show that 2-ME induces autophagosome and alters LC3-II to LC3-I ratio in wild type PKR expressing cells but not in cells expressing transdominant mutant PKR protein. It is possible that some of the downstream effects contribute to these various actions of PKR. However, further evidence is necessary to determine whether PKR contributes to interplay between autophagy and apoptosis, and that autophagy is required for cell death in 2-ME-treated osteosarcoma cells. Future investigations on molecular candidates associated with autophagy in 2-ME-treated cells could lead to improvement of treatment and development of better anti-cancer strategies in osteosarcoma patients.

**Author Contributions**

Contributed intellectually, and read and approved the final version of the manuscript: CY KLS RG DB MJY AM. Conceived and designed the experiments: CY KLS MJY AM. Performed the experiments: CY KLS RG DB. Analyzed the data: CY KLS RG DB MJY AM. Wrote the paper: AM.

**References**

1. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463–477.
2. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, et al. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 31–64.
3. Maiuri MC, Taddei E, Criollo A, Morelli E, Vicencio JM, et al. (2009) Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 16: 87–93.
4. Morelli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, et al. (2009) Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 1795: 1524–1532.
5. Qu X, Yu J, Bhagat G, Furuya N, Hishshoos H, et al. (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112: 1809–1820.

6. Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A 107: 14333–14338.
7. Huang S, Sinicrope FA Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 6: 236–249.
8. Maiuri MC, Criollo A, Taddei E, Vicencio JM, Tajedine N, et al. (2007) BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-XL. Autophagy 3: 374–376.
9. O’Donovan TR, O’Sullivan GC, McKenna SL Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 7: 509–524.
10. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, et al. (2008) Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 112: 389–403.

11. Miazghini S, Condello M, Calabrizzi A, Marra M, Fornisano G, et al. (2008) The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. Autophagy 4: 1020–1033.

12. Tornai D, Chiecchio A., Alonso-Curbelo D, Perez-Guijarro E, Cano E, et al. (2009) Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16: 103–114.

13. Turcotte S, Chan DA, Sunphun PD, Hay MP, Denny WA, et al. (2006) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14: 90–102.

14. Voss V, Senn C, Lang V, Ronellenfitsch MW, Steinbach JP, et al. The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8: 1002–1016.

15. Fotis T, Zhang Y, Pepper MS, Addecreutz H, Montesano R, et al. (1994) The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368: 237–239.

16. Garcia GE, Wimwieski HG, Luria MS, Arevalo N, Slaga TJ, et al. (2006) 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res 12: 980–988.

17. Kang SH, Cho HT, Zhang Z, Eecuin D, et al. (2006) Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 66: 11991–11997.

18. Kumar AP, Garcia GE, Orsborn J, Levin VA, Slaga TJ, et al. (2003) 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 24: 209–216.

19. LaVallee TM, Zhan XH, Johnson MS, Herbsttritt CJ, Swartz G, et al. (2006) 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63: 468–475.

20. Muhammad Z, Roth JA (1999) Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14: 379–384.

21. Qudah LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, et al. (2007) 2-Methoxyestradiol-induced apoptosis of human lung cancer cells. J Bone Miner Res 22: 29–36.

22. Benedikt MB, Mahlum EW, Shogren KL, Subramaniam M, Spelberg TC, et al. (2010) 2-Methoxyestradiol-mediated anti-tumor effect increases osteoprotegerin expression in osteosarcoma cells. J Cell Biochem 109: 950–956.

23. Maran A, Zhang M, Kennedy AM, Sibonga JD, Rickard DJ, et al. (2002) 2-Methoxyestradiol Induces Interferon Gene Expression and Apoptosis in Osteosarcoma Cells. Bone 30: 393–398.

24. Shogren KL, Turner RT, Yaseminzi MJ, Maran A (2007) Double-stranded RNA-dependent protein kinase is involved in 2-methoxyestradiol-mediated cell death of osteosarcoma cells. J Bone Miner Res 22: 29–36.

25. Maran A, Shogren KL, Benedikt M, Sarkar G, Turner RT, et al. (2008) 2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest. J Cell Biochem 104: 1937–1945.

26. Wimhauer F, Yang C, Shogren KL, Zhang M, Goyal R, et al. (2012) Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells. BMC Cancer 12: 93.

27. Kennedy AM, Shogren KL, Zhang M, Turner RT, Spelberg TC, et al. (2005) U78fra-stradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity. Endocrinology 146: 201–207.

28. Mann SS, Harhammer JA (1994) Molecular characterization of light chain 3. A microtubule binding subunit of MAP1A and MAP1B. J Biol Chem 269: 11492–11497.

29. Ichimura Y, Kirisako T, Takao T, Satomi Y, Shimomizu Y, et al. (2000) A ubiquitin-like system mediates protein liquidation. Nature 408: 488–492.

30. Tanida I, Ueno T, Komai N, et al. (2004) Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem 279: 47704–47710.

31. Mizushima N, Yoshinori T, Levine B (2006) Molecular basis of mammalian autophagy. Science 312: 1640–1645.

32. Ding WX, Ni HM, Gao W, Yoshinoh T, Stolz DB, et al. (2007) Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171: 515–524.

33. Ge FF, Zhang JZ, Wang XF, Meng FK, Li WW, et al. (2009) Inhibition of autophagy induced by protease inhibition increases cell death in human SHG-44 glioma cells. Acta Pharmacol Sin 30: 1046–1052.

34. Moscot J, Dziewan-MT (2009) p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137: 1001–1004.

35. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, et al. (2005) p62/ SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171: 603–614.

36. Kumar A, Hasg J, Lacoste J, Hiscott J, Williams BR (1994) Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA 91: 6280–6292.

37. Williams BR (1999) PKR, a sentinel kinase for cellular stress. Oncogene 18: 6112–6120.

38. Barber GN (2005) The dsRNA-dependent protein kinase, PKR and cell death. Cell Death Differ 12: 563–570.

39. Garcia MA, Gil J, Ventoso L, Guerra S, Domingo E, et al. (2006) Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70: 1032–1060.

40. Talloocy Z, Virgin HW, Levine B (2006) PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy 2: 24–29.

41. Lorin S, Borges A, Ribeiro Dos Santos L, Souquere S, Pierro G, et al. (2009) c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated Ewing sarcoma cells. Cancer Res 69: 6924–6931.

42. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB (2008) Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 15: 171–182.

43. Kirches E, Wirtz-Kriches M (2009) 2-methoxyestradiol as a potential cytostatic drug in gliomas? Anticancer Agents Med Chem 9: 55–63.

44. Parks M, Tillyon M, Dona F, Prosperi E, Scovassi AI (2011) 2-Methoxyestra- diol: new perspectives in colon carcinoma treatment. Mol Cell Endocrinol 331: 119–120.